{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T08:39:25Z","timestamp":1793176765766,"version":"4.5.0"},"reference-count":108,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016469","name":"Takeda Pharmaceuticals International","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016469","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.clcc.2026.04.001","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T06:23:54Z","timestamp":1776234234000},"page":"191-208","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Late-line Systemic Therapy in Metastatic Colorectal Cancer: A Narrative Review and Australian Expert Perspective"],"prefix":"10.1016","volume":"25","author":[{"given":"Matthew","family":"Burge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne","family":"Tie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tharani","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amitesh","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorraine","family":"Chantrill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niall C.","family":"Tebbutt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos S.","family":"Karapetis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.clcc.2026.04.001_bib0001","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clcc.2026.04.001_bib0002","unstructured":"Australian Institute of Health and Welfare. Cancer data in Australia. An overview of colorectal cancer in Australia. 2025. Available at: https:\/\/www.aihw.gov.au\/reports\/cancer\/cancer-data-in-australia\/contents\/cancer-data-commentaries\/an-overview-of-colorectal-cancer-in-australia. Accessed: August 11, 2025."},{"key":"10.1016\/j.clcc.2026.04.001_bib0003","series-title":"To View the Most Recent and Complete Version of the Guideline, Go Online to NCCN.Org. NCCN Makes no Warranties of any Kind Whatsoever Regarding Their Content, Use or Application and Disclaims any Responsibility for Their Application or Use in any Way","article-title":"NCCN clinical practice guidelines in oncology (NCCN guidelines\u00ae) for colon cancer V.5.2025","year":"2025"},{"issue":"1","key":"10.1016\/j.clcc.2026.04.001_bib0004","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.clcc.2026.04.001_bib0005","first-page":"660","article-title":"BRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapies","volume":"6","author":"Clarke","year":"2015","journal-title":"J Gastrointest Oncol"},{"issue":"17","key":"10.1016\/j.clcc.2026.04.001_bib0006","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer","volume":"381","author":"Kopetz","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clcc.2026.04.001_bib0007","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1200\/JCO.20.02088","article-title":"Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study","volume":"39","author":"Tabernero","year":"2021","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.clcc.2026.04.001_bib0008","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1056\/NEJMoa2308795","article-title":"Sotorasib plus panitumumab in refractory colorectal cancer with mutated KRAS G12C","volume":"389","author":"Fakih","year":"2023","journal-title":"N Engl J Med"},{"issue":"17 Suppl","key":"10.1016\/j.clcc.2026.04.001_bib0009","doi-asserted-by":"crossref","first-page":"LBA3510","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA3510","article-title":"Overall survival (OS) of phase 3 CodeBreaK 300 study of sotorasib plus panitumumab (soto+pani) versus investigator\u2019s choice of therapy for KRAS G12C-mutated metastatic colorectal cancer (mCRC)","volume":"42","author":"Fakih","year":"2024","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clcc.2026.04.001_bib0010","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1158\/2159-8290.CD-24-0217","article-title":"Efficacy and safety of adagrasib plus cetuximab in patients with KRASG12C-mutated metastatic colorectal cancer","volume":"14","author":"Yaeger","year":"2024","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.clcc.2026.04.001_bib0011","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1470-2045(16)00150-9","article-title":"Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12\/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial","volume":"17","author":"Sartore-Bianchi","year":"2016","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.clcc.2026.04.001_bib0012","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S1470-2045(18)30904-5","article-title":"Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study","volume":"20","author":"Meric-Bernstam","year":"2019","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.clcc.2026.04.001_bib0013","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1038\/s41591-021-01553-w","article-title":"Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial","volume":"27","author":"Nakamura","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.clcc.2026.04.001_bib0014","article-title":"Pertuzumab plus trastuzumab in patients with colorectal cancer with ERBB2 amplification or ERBB2\/3 mutations: results from the TAPUR study","volume":"6","author":"Gupta","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"5","key":"10.1016\/j.clcc.2026.04.001_bib0015","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000911","article-title":"Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the Phase II HERACLES-B trial","volume":"5","author":"Sartore-Bianchi","year":"2020","journal-title":"ESMO Open"},{"issue":"5","key":"10.1016\/j.clcc.2026.04.001_bib0016","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S1470-2045(23)00150-X","article-title":"Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study","volume":"24","author":"Strickler","year":"2023","journal-title":"Lancet Oncol"},{"issue":"16 Suppl","key":"10.1016\/j.clcc.2026.04.001_bib0017","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1200\/JCO.2024.42.16_suppl.3509","article-title":"Final results of a phase 2 study of tucatinib and trastuzumab for HER2-positive mCRC (MOUNTAINEER)","volume":"42","author":"Strickler","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clcc.2026.04.001_bib0018","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1038\/s41467-023-38032-4","article-title":"Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer","volume":"14","author":"Yoshino","year":"2023","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.clcc.2026.04.001_bib0019","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S1470-2045(24)00380-2","article-title":"Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial","volume":"25","author":"Raghav","year":"2024","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.clcc.2026.04.001_bib0020","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/s41591-024-03443-3","article-title":"Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial","volume":"31","author":"Kopetz","year":"2025","journal-title":"Nat Med"},{"issue":"24","key":"10.1016\/j.clcc.2026.04.001_bib0021","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa2501912","article-title":"Encorafenib, cetuximab, and mFOLFOX6 in BRAF-mutated colorectal cancer","volume":"392","author":"Elez","year":"2025","journal-title":"N Engl J Med"},{"issue":"7407","key":"10.1016\/j.clcc.2026.04.001_bib0022","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nature11252","article-title":"Comprehensive molecular characterization of human colon and rectal cancer","volume":"487","year":"2012","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.clcc.2026.04.001_bib0023","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1093\/oncolo\/oyac077","article-title":"Real-world study of characteristics and treatment outcomes among patients with KRAS p.G12C-mutated or other KRAS mutated metastatic colorectal cancer","volume":"27","author":"Fakih","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.clcc.2026.04.001_bib0024","article-title":"Comprehensive clinical and molecular characterization of KRAS (G12C)-mutant colorectal cancer","volume":"5","author":"Henry","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.clcc.2026.04.001_bib0025","unstructured":"US Food and Drug Administration. FDA approves sotorasib with panitumumab for KRAS G12C-mutated colorectal cancer. 2025. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-sotorasib-panitumumab-kras-g12c-mutated-colorectal-cancer. Accessed: May 12, 2025."},{"issue":"4 Suppl","key":"10.1016\/j.clcc.2026.04.001_bib0026","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1200\/JCO.2025.43.4_suppl.131","article-title":"Adagrasib (Ada) + cetuximab (Cetux) for KRASG12C-mutated metastatic colorectal cancer (mCRC): longer follow-up analysis from KRYSTAL-1","volume":"43","author":"Yaeger","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2026.04.001_bib0027","unstructured":"US Food and Drug Administration. FDA grants accelerated approval to adagrasib with cetuximab for KRAS G12C-mutated colorectal cancer. 2024. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-adagrasib-cetuximab-kras-g12c-mutated-colorectal-cancer. Accessed: May 12, 2025."},{"issue":"4 Suppl","key":"10.1016\/j.clcc.2026.04.001_bib0028","first-page":"TPS326","article-title":"A phase 3 study of first-line sotorasib, panitumumab, and FOLFIRI versus FOLFIRI with or without bevacizumab-awwb for patients with KRAS G12C-mutated metastatic colorectal cancer (CodeBreaK 301)","volume":"43","author":"Kim","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2026.04.001_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104515","article-title":"The emerging HER2 landscape in colorectal cancer: the key to unveil the future treatment algorithm?","volume":"204","author":"Venturini","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clcc.2026.04.001_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102488","article-title":"The predictive role of ERBB2 point mutations in metastatic colorectal cancer: a systematic review","volume":"112","author":"Vaghi","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clcc.2026.04.001_bib0031","unstructured":"US Food and Drug Administration. FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive solid tumors. 2024. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2. Accessed: May 14, 2025."},{"issue":"4 Suppl","key":"10.1016\/j.clcc.2026.04.001_bib0032","doi-asserted-by":"crossref","first-page":"TPS261","DOI":"10.1200\/JCO.2023.41.4_suppl.TPS261","article-title":"MOUNTAINEER-03: phase 3 study of tucatinib, trastuzumab, and mFOLFOX6 as first-line treatment in HER2+ metastatic colorectal cancer\u2014trial in progress","volume":"41","author":"Bekaii-Saab","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4 Suppl","key":"10.1016\/j.clcc.2026.04.001_bib0033","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1200\/JCO.2023.41.4_suppl.140","article-title":"A randomized phase 2 study of trastuzumab and pertuzumab (TP) compared to cetuximab and irinotecan (CETIRI) in advanced\/metastatic colorectal cancer (mCRC) with HER2 amplification: SWOG S1613","volume":"41","author":"Raghav","year":"2023","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.clcc.2026.04.001_bib0034","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clcc.2026.04.001_bib0035","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ejca.2023.02.016","article-title":"Pembrolizumab for previously treated, microsatellite instability-high\/mismatch repair-deficient advanced colorectal cancer: final analysis of KEYNOTE-164","volume":"186","author":"Le","year":"2023","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1016\/j.clcc.2026.04.001_bib0036","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol"},{"issue":"10476","key":"10.1016\/j.clcc.2026.04.001_bib0037","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0140-6736(24)02848-4","article-title":"Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial","volume":"405","author":"Andr\u00e9","year":"2025","journal-title":"Lancet"},{"issue":"2_suppl","key":"10.1016\/j.clcc.2026.04.001_bib0038","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1200\/JCO.2026.44.2_suppl.14","volume":"44","author":"Rocha Lima","year":"2026","journal-title":"J Clin Oncol"},{"issue":"4 Suppl","key":"10.1016\/j.clcc.2026.04.001_bib0039","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1200\/JCO.2025.43.4_suppl.23","article-title":"Preliminary results from a randomized, open-label, phase 2 study of botensilimab (BOT) with or without balstilimab (BAL) in refractory microsatellite stable metastatic colorectal cancer with no liver metastases (MSS mCRC NLM)","volume":"43","author":"Fakih","year":"2025","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.clcc.2026.04.001_bib0040","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1038\/s41591-024-03083-7","article-title":"Botensilimab plus balstilimab in relapsed\/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial","volume":"30","author":"Bullock","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.clcc.2026.04.001_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101917","article-title":"Regorafenib plus nivolumab in patients with mismatch repair-proficient\/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study","volume":"58","author":"Fakih","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"4 Suppl","key":"10.1016\/j.clcc.2026.04.001_bib0042","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1200\/JCO.2023.41.4_suppl.110","article-title":"Regorafenib, ipilimumab, and nivolumab (RIN) in chemotherapy-resistant MSS metastatic colorectal cancer (mCRC)","volume":"41","author":"Fakih","year":"2023","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clcc.2026.04.001_bib0043","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1001\/jamaoncol.2022.7845","article-title":"Regorafenib, ipilimumab, and nivolumab for patients with microsatellite stable colorectal cancer and disease progression with prior chemotherapy: a phase 1 nonrandomized clinical trial","volume":"9","author":"Fakih","year":"2023","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.clcc.2026.04.001_bib0044","doi-asserted-by":"crossref","first-page":"7255","DOI":"10.1038\/s41467-024-51536-x","article-title":"Tislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: a single-arm phase 2 study","volume":"15","author":"Xu","year":"2024","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.clcc.2026.04.001_bib0045","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.ctrv.2014.02.006","article-title":"A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with fluorouracil, oxaliplatin and irinotecan \u00b1 targeted therapy","volume":"40","author":"Nielsen","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clcc.2026.04.001_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102112","article-title":"Oxaliplatin retreatment in metastatic colorectal cancer: systematic review and future research opportunities","volume":"91","author":"Mauri","year":"2020","journal-title":"Cancer Treat Rev"},{"issue":"20","key":"10.1016\/j.clcc.2026.04.001_bib0047","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"Mayer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clcc.2026.04.001_bib0048","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejca.2017.10.009","article-title":"The subgroups of the Phase III RECOURSE trial of trifluridine\/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer","volume":"90","author":"Van Cutsem","year":"2018","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.clcc.2026.04.001_bib0049","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1200\/JCO.2017.74.3245","article-title":"Results of a randomized, double-blind, placebo-controlled, phase III trial of trifluridine\/tipiracil (TAS-102) monotherapy in Asian patients with previously treated metastatic colorectal cancer: the TERRA study","volume":"36","author":"Xu","year":"2018","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.clcc.2026.04.001_bib0050","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","article-title":"Trifluridine\u2013tipiracil and bevacizumab in refractory metastatic colorectal cancer","volume":"388","author":"Prager","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clcc.2026.04.001_bib0051","first-page":"1728","article-title":"Efficacy and safety of trifluridine\/tipiracil plus bevacizumab across different subgroups of patients with refractory colorectal cancer: a meta-analysis","volume":"18","author":"da Silva","year":"2024","journal-title":"Ecancermedicalscience"},{"issue":"Suppl 2","key":"10.1016\/j.clcc.2026.04.001_bib0052","doi-asserted-by":"crossref","first-page":"S440","DOI":"10.1016\/j.annonc.2023.09.1805","article-title":"Effect of KRASG12 mutations on overall survival in patients with refractory metastatic colorectal cancer: a post-hoc analysis of the Phase III SUNLIGHT trial","volume":"34","author":"Tabernero","year":"2023","journal-title":"Ann Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.clcc.2026.04.001_bib0053","doi-asserted-by":"crossref","first-page":"S1218","DOI":"10.1016\/j.annonc.2024.08.2264","article-title":"Randomized Phase III trial of ramucirumab in combination with TAS102 (trifluridin\/tipiracil) vs. TAS102 monotherapy in heavily pretreated metastatic colorectal cancer: the RAMTAS\/IKF643 trial of the German AIO (AIO-KRK-0316)","volume":"35","author":"Kasper-Virchow","year":"2024","journal-title":"Ann Oncol"},{"issue":"9863","key":"10.1016\/j.clcc.2026.04.001_bib0054","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.clcc.2026.04.001_bib0055","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1470-2045(15)70156-7","article-title":"Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"16","author":"Li","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2026.04.001_bib0056","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ctrv.2017.10.011","article-title":"Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: a systematic review","volume":"62","author":"R\u00f8ed Sk\u00e5rderud","year":"2018","journal-title":"Cancer Treat Rev"},{"issue":"24","key":"10.1016\/j.clcc.2026.04.001_bib0057","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.2018.7855","article-title":"Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: the FRESCO randomized clinical trial","volume":"319","author":"Li","year":"2018","journal-title":"JAMA"},{"issue":"10395","key":"10.1016\/j.clcc.2026.04.001_bib0058","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0140-6736(23)00772-9","article-title":"Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study","volume":"402","author":"Dasari","year":"2023","journal-title":"Lancet"},{"issue":"16 Suppl","key":"10.1016\/j.clcc.2026.04.001_bib0059","article-title":"Overall survival with fruquintinib versus placebo after adjusting for subsequent anticancer therapy in patients with refractory metastatic colorectal cancer in the FRESCO-2 study","volume":"43","author":"Lonardi","year":"2025","journal-title":"J Clin Oncol"},{"issue":"4 Suppl","key":"10.1016\/j.clcc.2026.04.001_bib0060","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1200\/JCO.2023.41.4_suppl.67","article-title":"Health-related quality of life (HRQoL) associated with fruquintinib in the global phase 3, placebo-controlled, double-blind FRESCO-2 study","volume":"41","author":"Sobrero","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.clcc.2026.04.001_bib0061","doi-asserted-by":"crossref","first-page":"e1012","DOI":"10.1093\/oncolo\/oyae073","article-title":"A phase IV study to evaluate the safety of fruquintinib in Chinese patients in real-world clinical practice","volume":"29","author":"Li","year":"2024","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.clcc.2026.04.001_bib0062","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101558","article-title":"Pan-Asian adapted ESMO clinical practice guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer","volume":"8","author":"Yoshino","year":"2023","journal-title":"ESMO Open"},{"issue":"4 Suppl","key":"10.1016\/j.clcc.2026.04.001_bib0063","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1200\/JCO.2025.43.4_suppl.145","article-title":"Updated analysis of a phase 2 study of fruquintinib plus trifluridine\/tipiracil (TAS-102) as third-line treatment in patients with metastatic colorectal adenocarcinoma","volume":"43","author":"Peng","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2026.04.001_bib0064","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.113975","article-title":"A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness","volume":"202","author":"Yoshino","year":"2024","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.clcc.2026.04.001_bib0065","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2018-000353","article-title":"Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer","volume":"3","author":"Goldberg","year":"2018","journal-title":"ESMO Open"},{"issue":"7","key":"10.1016\/j.clcc.2026.04.001_bib0066","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/nm0715-827b","article-title":"Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients","volume":"21","author":"Siravegna","year":"2015","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.clcc.2026.04.001_bib0067","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/jamaoncol.2018.5080","article-title":"Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical trial","volume":"5","author":"Cremolini","year":"2019","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.clcc.2026.04.001_bib0068","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1038\/s41416-020-01042-w","article-title":"Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08","volume":"123","author":"Masuishi","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clcc.2026.04.001_bib0069","doi-asserted-by":"crossref","first-page":"S433","DOI":"10.1016\/j.annonc.2024.08.580","article-title":"Third line rechallenge with cetuximab (Cet) and irinotecan in circulating tumor DNA (ctDNA) selected metastatic colorectal cancer (mCRC) patients: the randomized Phase II CITRIC trial","volume":"35","author":"Vivas","year":"2024","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.clcc.2026.04.001_bib0070","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1001\/jamaoncol.2021.2915","article-title":"Cetuximab rechallenge plus avelumab in pretreated patients with RAS wild-type metastatic colorectal cancer: the phase 2 single-arm clinical CAVE trial","volume":"7","author":"Martinelli","year":"2021","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.clcc.2026.04.001_bib0071","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s11523-021-00845-y","article-title":"Phase II study of third-line panitumumab rechallenge in patients with metastatic wild-type KRAS colorectal cancer who obtained clinical benefit from first-line panitumumab-based chemotherapy: JACCRO CC-09","volume":"16","author":"Tsuji","year":"2021","journal-title":"Target Oncol"},{"issue":"8","key":"10.1016\/j.clcc.2026.04.001_bib0072","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1038\/s41591-022-01886-0","article-title":"Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial","volume":"28","author":"Sartore-Bianchi","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.clcc.2026.04.001_bib0073","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.940523","article-title":"CAVE-2 (Cetuximab-AVElumab) mCRC: a phase II randomized clinical study of the combination of avelumab plus cetuximab as a rechallenge strategy in pre-treated RAS\/BRAF wild-type mCRC patients","volume":"12","author":"Napolitano","year":"2022","journal-title":"Front Oncol"},{"issue":"8","key":"10.1016\/j.clcc.2026.04.001_bib0074","doi-asserted-by":"crossref","first-page":"9392","DOI":"10.1002\/cam4.5699","volume":"12","author":"Martini","year":"2023","journal-title":"Cancer Med"},{"issue":"4 Suppl","key":"10.1016\/j.clcc.2026.04.001_bib0075","doi-asserted-by":"crossref","first-page":"TPS264","DOI":"10.1200\/JCO.2023.41.4_suppl.TPS264","article-title":"TRIDENTE trial: a Phase II study of rechallenge with encorafenib, binimetinib, and cetuximab in patients with RAS wild-type\/BRAF V600E-mutant metastatic colorectal cancer","volume":"41","author":"Kotani","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2026.04.001_bib0076","article-title":"Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trial","volume":"13","author":"Germani","year":"2023","journal-title":"Front Oncol"},{"issue":"2 D","key":"10.1016\/j.clcc.2026.04.001_bib0077","article-title":"Colon cancer, version 3.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Benson","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"21","key":"10.1016\/j.clcc.2026.04.001_bib0078","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMoa2402141","article-title":"Nivolumab plus ipilimumab in microsatellite-instability-high metastatic colorectal cancer","volume":"391","author":"Andr\u00e9","year":"2024","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.clcc.2026.04.001_bib0079","doi-asserted-by":"crossref","first-page":"S174","DOI":"10.1016\/j.annonc.2023.04.501","article-title":"Clinical characteristics, efficacy, and safety in patients receiving second- or third-line encorafenib plus cetuximab (E+C) vs control for metastatic colorectal cancer (mCRC): BEACON CRC post hoc analysis","volume":"34","author":"Tabernero","year":"2023","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.clcc.2026.04.001_bib0080","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1038\/s41591-024-03235-9","article-title":"Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase\u20093 BEACON CRC trial","volume":"30","author":"Kopetz","year":"2024","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.clcc.2026.04.001_bib0081","first-page":"215","article-title":"BRAF(V600E)-mutant metastatic colorectal cancer: current evidence, future directions, and research priorities","volume":"23","author":"Piercey","year":"2024","journal-title":"Clin Colorectal Cancer"},{"issue":"4","key":"10.1016\/j.clcc.2026.04.001_bib0082","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","article-title":"Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials","volume":"21","author":"Hong","year":"2020","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.clcc.2026.04.001_bib0083","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1158\/1078-0432.CCR-21-3597","article-title":"Updated integrated analysis of the efficacy and safety of entrectinib in patients with NTRK fusion-positive solid tumors","volume":"28","author":"Demetri","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.clcc.2026.04.001_bib0084","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41591-025-04079-7","article-title":"Repotrectinib in NTRK fusion-positive advanced solid tumors: a phase 1\/2 trial","volume":"32","author":"Besse","year":"2026","journal-title":"Nat Med"},{"key":"10.1016\/j.clcc.2026.04.001_bib0085","unstructured":"US Food and Drug Administration. FDA approves larotrectinib for solid tumors with NTRK gene fusions, 2018. Available at: https:\/\/www.fda.gov\/drugs\/fda-approves-larotrectinib-solid-tumors-ntrk-gene-fusions-0. Accessed: February 20, 2026."},{"key":"10.1016\/j.clcc.2026.04.001_bib0086","unstructured":"US Food and Drug Administration. FDA approves entrectinib for NTRK solid tumors and ROS-1 NSCLC, 2019. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-entrectinib-ntrk-solid-tumors-and-ros-1-nsclc. Accessed: February 20, 2026."},{"issue":"3 Suppl","key":"10.1016\/j.clcc.2026.04.001_bib0087","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1200\/JCO.2024.42.3_suppl.746","article-title":"Durable efficacy of selpercatinib in patients with RET fusion+ solid tumors, with a focus on GI tumors: LIBRETTO-001","volume":"42","author":"Subbiah","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clcc.2026.04.001_bib0088","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1186\/s12885-016-2734-y","article-title":"Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis","volume":"16","author":"Botrel","year":"2016","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.clcc.2026.04.001_bib0089","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jamcollsurg.2011.12.030","article-title":"Bevacizumab-associated fistula formation in postoperative colorectal cancer patients","volume":"214","author":"Ganapathi","year":"2012","journal-title":"J Am Coll Surg"},{"issue":"2","key":"10.1016\/j.clcc.2026.04.001_bib0090","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00384-019-03477-x","article-title":"Regorafenib, TAS-102, or fruquintinib for metastatic colorectal cancer: any difference in randomized trials?","volume":"35","author":"Zhang","year":"2020","journal-title":"Int J Colorectal Dis"},{"key":"10.1016\/j.clcc.2026.04.001_bib0091","doi-asserted-by":"crossref","first-page":"9179","DOI":"10.12659\/MSM.918411","article-title":"Comparison of regorafenib, fruquintinib, and TAS-102 in previously treated patients with metastatic colorectal cancer: a systematic review and network meta-analysis of five clinical trials","volume":"25","author":"Chen","year":"2019","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.clcc.2026.04.001_bib0092","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920940932","article-title":"Efficacy and safety of regorafenib as beyond second-line therapy in patients with metastatic colorectal cancer: an adjusted indirect meta-analysis and systematic review","volume":"12","author":"Wu","year":"2020","journal-title":"Ther Adv Med Oncol"},{"issue":"6","key":"10.1016\/j.clcc.2026.04.001_bib0093","doi-asserted-by":"crossref","first-page":"5456","DOI":"10.3390\/curroncol30060413","article-title":"Treatment settings and outcomes with regorafenib and trifluridine\/tipiracil at third-line treatment and beyond in metastatic colorectal cancer: a real-world multicenter retrospective study","volume":"30","author":"Signorelli","year":"2023","journal-title":"Curr Oncol"},{"issue":"3","key":"10.1016\/j.clcc.2026.04.001_bib0094","first-page":"e152","article-title":"Efficacy and safety comparison of regorafenib and fruquintinib in metastatic colorectal cancer\u2014an observational cohort study in the real world","volume":"21","author":"Zhang","year":"2022","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.clcc.2026.04.001_bib0095","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1097911","article-title":"Comparison of the efficacy and safety of fruquintinib and regorafenib in the treatment of metastatic colorectal cancer: a real-world study","volume":"13","author":"Deng","year":"2023","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.clcc.2026.04.001_bib0096","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/annonc\/mdy509","article-title":"Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge","volume":"30","author":"Parseghian","year":"2019","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.clcc.2026.04.001_bib0097","doi-asserted-by":"crossref","first-page":"7793","DOI":"10.3390\/curroncol31120574","article-title":"Survival outcomes with regorafenib and\/or trifluridine\/tipiracil sequencing to rechallenge with third-line regimens in metastatic colorectal cancer: a multicenter retrospective real-world subgroup comparison from the ReTrITA study","volume":"31","author":"Signorelli","year":"2024","journal-title":"Curr Oncol"},{"issue":"17 Suppl","key":"10.1016\/j.clcc.2026.04.001_bib0098","first-page":"LBA3515","article-title":"Panitumumab retreatment followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA (ctDNA): results of the Phase II randomized PARERE trial by GONO","volume":"43","author":"Cremolini","year":"2025","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.clcc.2026.04.001_bib0099","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/s41416-023-02213-1","article-title":"Liver transplantation in metastatic colorectal cancer: are we ready for it?","volume":"128","author":"Ros","year":"2023","journal-title":"Br J Cancer"},{"issue":"9","key":"10.1016\/j.clcc.2026.04.001_bib0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103669","article-title":"Translating efficacy of liver transplantation in liver-limited metastatic colorectal cancer into clinical practice: the TransMet trial","volume":"9","author":"Germani","year":"2024","journal-title":"ESMO Open"},{"issue":"10458","key":"10.1016\/j.clcc.2026.04.001_bib0101","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(24)01595-2","article-title":"Liver transplantation plus chemotherapy versus chemotherapy alone in patients with permanently unresectable colorectal liver metastases (TransMet): results from a multicentre, open-label, prospective, randomised controlled trial","volume":"404","author":"Adam","year":"2024","journal-title":"Lancet"},{"issue":"16 Suppl","key":"10.1016\/j.clcc.2026.04.001_bib0102","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1200\/JCO.2024.42.16_suppl.3515","article-title":"First-in-human study of ABBV-400, a novel c-met\u2013targeting antibody-drug conjugate, in advanced solid tumors: results in colorectal cancer","volume":"42","author":"Sharma","year":"2024","journal-title":"J Clin Oncol"},{"issue":"15 Suppl","key":"10.1016\/j.clcc.2026.04.001_bib0103","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1200\/JCO.2017.35.15_suppl.3557","article-title":"A phase I\/II trial of combined BRAF and EGFR inhibition in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal (mCRC): the EViCT (Erlotinib and Vemurafenib in Combination Trial) study","volume":"35","author":"Desai","year":"2017","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.clcc.2026.04.001_bib0104","doi-asserted-by":"crossref","first-page":"4341","DOI":"10.21873\/anticanres.16629","article-title":"Cetuximab enhances the efficacy of MRTX1133, a novel KRAS(G12D) inhibitor, in colorectal cancer treatment","volume":"43","author":"Kataoka","year":"2023","journal-title":"Anticancer Res"},{"issue":"4 Suppl","key":"10.1016\/j.clcc.2026.04.001_bib0105","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1200\/JCO.2025.43.4_suppl.182","article-title":"Phase I\/II trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAFV600E metastatic colorectal cancer following progression on prior BRAF+EGFR targeted therapies","volume":"43","author":"Pan","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2026.04.001_bib0106","unstructured":"Exelixis Inc. Exelixis announces zanzalintinib in combination with an immune checkpoint inhibitor improved overall survival in STELLAR-303 phase 3 pivotal trial in patients with metastatic colorectal cancer. 2025. Available at: https:\/\/ir.exelixis.com\/news-releases\/news-release-details\/exelixis-announces-zanzalintinib-combination-immune-checkpoint2025. Accessed: August 11, 2025."},{"issue":"16 Suppl","key":"10.1016\/j.clcc.2026.04.001_bib0107","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1200\/JCO.2025.43.16_suppl.3517","article-title":"Phase 2 dose expansion study of DSP107, a first-in-class bi-specific 4-1BB T-cell engager, with and without atezolizumab in metastatic MSS colorectal cancer patients","volume":"43","author":"Saeed","year":"2025","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clcc.2026.04.001_bib0108","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1186\/s12885-025-13654-7","article-title":"Raltitrexed, S-1 and fruquintinib (RSF) in the treatment of refractory metastatic colorectal cancer: study protocol for a multicenter, prospective, single-arm, phase II trial","volume":"25","author":"Leng","year":"2025","journal-title":"BMC Cancer"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002826000241?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002826000241?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T08:26:03Z","timestamp":1793175963000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002826000241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":108,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1533002826000241"],"URL":"https:\/\/doi.org\/10.1016\/j.clcc.2026.04.001","relation":{},"ISSN":["1533-0028"],"issn-type":[{"value":"1533-0028","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Late-line Systemic Therapy in Metastatic Colorectal Cancer: A Narrative Review and Australian Expert Perspective","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clcc.2026.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}